Home
About Us
Background
Leadership
Collaborators
Accreditation
Technology
Telomere Science
TeloView®
Conference Presentations
Publications
IP
Multiple Myeloma
Overview
Smoldering Multiple Myeloma
MRD Solutions
Mayo Clinic
Investors
Physician Portal
Contact Us
Inquiries
Careers
Conference Presentations
Abstract Posters
Publication
Conference
Automated myeloma cell selection using machine learning and artificial intelligence
Journal of Clinical Oncology
ASCO 2024
The 3D- Telomere Profiling Assay Identifies High Risk Smoldering Multiple Myeloma Patients with High Precision
Blood
ASH 2023
High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping
Clinical Lymphoma Myeloma
&
Leukemia
IMS 2023
Three-dimensional telomere profiling predicts risk of relapse in newly diagnosed multiple myeloma patients
HemaSphere
EHA 2023
Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma
Journal of Clinical Oncology
ASCO 2023
Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort
Blood
ASH 2020
Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis
Blood
ASH 2020
Abstract Posters
Publication
Automated myeloma cell selection using machine learning and artificial intelligence
The 3D- Telomere Profiling Assay Identifies High Risk Smoldering Multiple Myeloma Patients with High Precision
High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping
Three-dimensional telomere profiling predicts risk of relapse in newly diagnosed multiple myeloma patients
Three-dimensional telomere profiling to predict risk of progression in smoldering multiple myeloma
Three-Dimensional Telomere Analysis Using Teloview® Technology Identifies Smouldering Myeloma Patients with High Risk of Progression to Full Stage Multiple Myeloma in a Proof of Concept Cohort
Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis